Raphael Pharmaceutical (RAPH) Invested Capital (2020 - 2025)

Raphael Pharmaceutical has disclosed Invested Capital across 6 years of filings, most recently posting -$1.4 million for Q4 2025.

• Invested Capital for Q4 2025 came in at -$1.4 million, down 99.57% year-over-year; the trailing twelve-month figure through Dec 2025 was -$1.4 million (down 99.57% YoY), and the FY2025 annual result was -$1.4 million, down 99.57% from the prior year.
• Invested Capital came in at -$1.4 million for Q4 2025 at Raphael Pharmaceutical, down from -$1.2 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $191000.0 in Q2 2021 to a low of -$1.4 million in Q4 2025.
• The 5-year median for Invested Capital is -$89000.0 (2023), against an average of -$293450.0.
• Across the five-year window, Invested Capital soared 541.18% in 2021 and plunged 1044.44% in 2024, its largest moves.
• Raphael Pharmaceutical's Invested Capital stood at $150000.0 in 2021, then dropped by 27.33% to $109000.0 in 2022, then slipped by 1.83% to $107000.0 in 2023, then slumped by 755.14% to -$701000.0 in 2024, then tumbled by 99.57% to -$1.4 million in 2025.
• The last three Invested Capital figures came in at -$1.4 million (Q4 2025), -$1.2 million (Q3 2025), and -$1.0 million (Q2 2025), per Business Quant data.